143 results on '"Yasuda, Nobuyuki"'
Search Results
2. Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs.
3. Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate.
4. Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate
5. Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs
6. The Fractalkine‐CX3CR1 Axis Regulates Non‐inflammatory Osteoclastogenesis by Enhancing Precursor Cell Survival
7. Comparison of Medically Versus Surgically Treated Acute Type A Aortic Dissection in Patients
8. Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases
9. Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study
10. A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs
11. Comparison of Efficacies of a Dipeptidyl Peptidase IV Inhibitor and α-Glucosidase Inhibitors in Oral Carbohydrate and Meal Tolerance Tests and the Effects of Their Combination in Mice
12. The prognostic value of treadmill exercise testing in very elderly patients: heart rate recovery as a predictor of mortality in octogenarians
13. Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
14. E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor
15. E3024 Is a Novel, Selective and Competitive Dipeptidy1 Peptidase-TV Inhibitor for the Treatment of Type 2 Diabetes: 1499-P
16. Effects of the Combination of a Novel Dipeptidy1 Peptidase IV Inhibitor and an Insulin Secretagogue on Glucose and Insulin Levels in Mice and Rats: 1497-P
17. Comparison of Efficacy of a Novel Dipeptidy1 Peptidase IV Inhibitor and (α-Glucosidase Inhibitors in Oral Carbohydrate and Meal Tolerance Tests, and Their Combination Effects in Mice: 1496-P
18. The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight
19. Functional characterization of the adenosine receptor contributing to glycogenolysis and gluconeogenesis in rat hepatocytes
20. Law and development in ASEAN countries
21. SAT0126 A PHASE 2 STUDY OF E6011, AN ANTI-FRACTALKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO BIOLOGICS
22. SAT0048 ANTI-FRACTALKINE MONOCLONAL ANTIBODY AMELIORATE JOINT DESTRUCTION AND SYNOVIUM THROUGH SUPPRESSION OF OSTEOCLAST PRECURSOR MIGRATION AND INDUCTION OF SYNOVIAL CELL DEATH IN COLLAGEN-INDUCED ARTHRITIS MODEL
23. OP0223 EFFICACY AND SAFETY OF E6011, AN ANTI-FRACTALKINE MONOCLONAL ANTIBODY, IN MTX-IR PATIENTS WITH RHEUMATOID ARTHRITIS
24. Blockade of the fractalkine–CX3CR1 axis ameliorates experimental colitis by dislodging venous crawling monocytes
25. Role of Anti‐Fractalkine Antibody in Suppression of Joint Destruction by Inhibiting Migration of Osteoclast Precursors to the Synovium in Experimental Arthritis
26. Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double‐Blind, Placebo‐Controlled Single‐Ascending‐Dose Study
27. Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats
28. Genba-Ryoku Note (Spring 2012)
29. 'Genba-Ryoku' Note (Fall 2010)
30. Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis
31. A Personal Reminiscence of Forty Years of Asian Law Study : From Asian Law Research to Law and Development Study
32. Anti-CX3CL1 monoclonal antibody: A promising therapy for systemic sclerosis
33. Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double‐Blind, Placebo‐Controlled Single‐Ascending‐Dose Study.
34. Report Ⅲ:The Evolution of Competition Law in East Asia Region
35. Report Ⅰ: On 'Asianness': Preliminary Research on Human Rights and Rights in Asian Contexts
36. Southeast Asian Law in Transition: The Law and Political, Economic and Social Systems in the Post Crisis of 1997
37. Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway
38. Mo1682 Inflammation via the Fractalkine (CX3CL1)/CX3CR1 Pathway Is Distinct From the TNF Pathway in Murine Colitis Model
39. Clinical outcomes and prognostic factor for acute heart failure in nonagenarians: Impact of hypoalbuminemia on mortality
40. Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of E3024, a Novel and Selective Dipeptidyl Peptidase-IV Inhibitor, in Healthy Japanese Male Subjects: Rash Development in Men and Its Possible Mechanism
41. The Characteristic of Premature Ventricular Complex from Right Ventricular Outflow Tract Inducing Idiopathic Ventricular Fibrillation and Ventricular Tachycardia
42. Does N-Acetylcysteine Reduce the Incidence of Contrast-Induced Nephropathy and Clinical Events in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction?
43. AS-146: Clinical Outcomes of Coronary Revascularization for Restenosis Lesions after Cypher Stent Implantation
44. AS-111: Early and Long-Term Outcomes of MULTI-LINK VISION Stent
45. AS-215: Can N-Acetylcysteine Reduce Contrast-Induced Nephropathy and Clinical Events in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction?
46. Effects of the Combination of a Dipeptidyl Peptidase IV Inhibitor and an Insulin Secretagogue on Glucose and Insulin Levels in Mice and Rats
47. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one Is a Novel Competitive and Selective Inhibitor of Dipeptidyl Peptidase IV with an Antihyperglycemic Activity
48. Therapeutic potential of DPP-IV inhibitor for the treatment of Type 2 diabetes
49. Metformin Causes Reduction of Food Intake and Body Weight Gain and Improvement of Glucose Intolerance in Combination with Dipeptidyl Peptidase IV Inhibitor in Zucker fa/fa Rats
50. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.